Investor Hits BioMimetic With Fraud Action

Law360, New York (July 7, 2011, 6:49 PM EDT) -- A BioMimetic Therapeutics Inc. investor filed a securities class action Wednesday in Tennessee accusing the medical device maker of lying about the progress of approval for a new bone injury treatment, causing its stock price to plummet when a safety panel questioned the product's potential to cause cancer.

Investor Paula Kuyat brought the suit on behalf of those who purchased BioMimetic stock between Oct. 14, 2009, and May 11, during which time the company assured investors that its new product, Augment Bone Graft, was doing well...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Kuyat v. BioMimetic Therapeutics, Inc. et al


Case Number

3:11-cv-00653

Court

Tennessee Middle

Nature of Suit

Securities/Commodities

Judge

Kevin H. Sharp

Date Filed

July 6, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.